

TRANSLATIONAL BREAST CANCER RESEARCH

A JOURNAL FOCUSING ON TRANSLATIONAL RESEARCH IN BREAST CANCER

2024 ANNUAL REPORT

Editorial Office tbcr@amegroups.com



Outline of the Report

- 1. General Information
- 2. Editor-in-Chief
- 3. Geographic Distribution of Editorial Board Members
- 4. Number of Published Articles in 2024
- 5. Type of Articles Published in 2024
- 6. Geographic Distribution of 2024 Corresponding Authors
- 7. Website Visits in 2024
- 8. Pageviews in 2024
- 9. Most Read Article Published in TBCR (2024)
- 10. Reviewer of the Month (2024)
- 11. Interviews with Outstanding Authors (2024)
- 12. Interview with Editorial Board Member (2024)
- 13. Cover Image Display
- 14. 2025 Events
- 15. Introduction to the Publisher AME



1. General Information



Picture of **Stephen D. Wang**, CEO and Founder of AME & **Zefei Jiang**, Editor-in-Chief of TBCR

Translational Breast Cancer Research

- Formally launched in November 2019
- Open-access & Peer-review
- Quarterly publication
- Indexed by PubMed on May 9, 2024
- Indexed by Web of Science [Emerging Sources Citation Index (ESCI)] on March 20, 2024
- Member of Committee on Publication Ethics (COPE)

TBCR focuses on translational research in breast cancer and contains articles dealing with laboratory investigations as well as clinical studies.



2. Editor-in-Chief



Editor-in-Chief

Prof. Zefei Jiang, MD Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China





◆ Message from Editor-in-Chief


"On behalf of TBCR Editorial Team, I would like to express our heartfelt appreciation to all the editorial board members, authors, reviewers, and readers for your enthusiastic and vigorous support and contributions to the journal, and we look forward to the cooperation and joint efforts of more colleagues in this endeavor to explore on breast cancer. Wish we can work closely with you in the new year!"

> Prof. Zefei Jiang, MD Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China





3. Geographic Distribution of Editorial Board Members



In 2024, the number of editorial board members amounted to 79, with leading domestic and overseas experts joining us, mainly from China, USA, Italy, Japan, Germany and UK, etc.




A Collage of TBCR Editorial Team Members





4. Number of Published Articles in 2024




As a quarterly publication, TBCR published four issues in 2024.





5. Type of Articles Published in 2024




- 16 Review Articles
- 9 Editorial/Editorial Commentary
- **5** Case Reports
- **3** Original Articles
- 1 Expert Consensus
- 1 Clinical Practice Guideline
- 1 Brief Report

TBCR published 36 pieces of articles in 2024, among which there are Review Article, Case Report, Original Article, and other types.




6. Geographic Distribution of 2024 Corresponding Authors



In 2024, 36 corresponding authors came from 11 countries in TBCR, most of whom came from China, USA and Brazil, et al.



7. Website Visits in 2024



Others (including Australia, Austria, Netherlands, Singapore, Korea, Greece, Brazil, etc.)

Country	Visits
USA	9,287
China	4,744
India	2,072
UK	1,235
Italy	894
Japan	849
Canada	827
Other	14,875

All together **34,783** visitors between Jan. 2024 and Dec. 2024. Readers who visited TBCR website in this period were from 177 regions and countries, with the majority from USA, followed by China, India, UK, Italy, etc.



8. Pageviews in 2024



The pageviews of TBCR between Jan. 2024 and Dec. 2024 have increased, and the traffic reached 110,410 in total, and the average number of Pageviews per month reached 9,200





9. Most Read Article Published in TBCR (2024)

Title	Corresponding Author	Country	Pageviews
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024	Zefei Jiang	China	5,658
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024	Zefei Jiang	China	4,633
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives	Mahira Lopes Rosa	Brazil	3,944
Challenges in HER2-low breast cancer identification, detection, and treatment	Ling Xu	China	3,831

Data source: https://tbcr.amegroups.org/article/mostRead?queryYear=2024; Collected on December 31, 2024



9. Most Read Article Published in TBCR (2024)

Title	Corresponding Author	Country	Pageviews
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer	Eleonora Nicolò	Italy	3,534
Evolution of localization methods for non- palpable breast lesions: a literature review from a translational medicine perspective	Ava Kwong	Hongkong, China	3,439
Breast fat grafting and cancer: a systematic review of the science behind enhancements and concerns	Denis Souto Valente	Brazil	2,966
Internal mammary lymphadenopathy in breast cancer: a narrative review and update	Mara A. Piltin	USA	2,854

Data source: https://tbcr.amegroups.org/article/mostRead?queryYear=2024; Collected on December 31, 2024



10. Reviewer of the Month (2024)

In 2024, TBCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Carlos H Barrios



Dr. Carlos H. Barrios is a medical oncologist working in Porto Alegre, Brazil. Dedicated mainly to Breast Cancer patients, he has an intense clinical research agenda both in their hospital research center and Latin American

Cooperative Oncology countries. He has beer Latin America and he is become important play income countries (LMI/d directed to diseases ar disproportional challen expected in the next fe outcomes. clinical rese

"Research is vital to procentral to the evolution others. Peer review in a

ensuring credibility, validity, and academic integrity of scientific manuscript by experts, who assess the study's methodology, robust, the conclusions are supported by the data, and the wave review maintains the trustworthiness of scientific literature an improving several different aspects of any manuscript, from the of the experiment, analysis of the results and the clarity and a improving the quality of the presented work.





Simone Nardin graduated from the University of Eastern Piedmont under the guidance of Professor Alessandra Gennari. Currently, he is a fellow in medical oncology at the University of Genoa, under the mentorship of Professor Lucia Del Mastro and Professor Matteo Lambertini, while working at IRCCS Ospedale Policlinico San Martino as an intern in the oncology department. His principal research areas are related to breast cancer, especially issues concerning young women and early treatment. Recent projects, worthy of ESMO Breast Cancer 2024 merit, focus on adjuvant endocrine therapy for premenopausal women and the role of GnRH analogs for these patients. Connect with him on LinkedIn.

In Dr. Nardin's opinion, the peer-review system is essential to ensure high standards during the publication process, as it is not feasible for editors to adequately assess the quality of every submitted manuscript. However, there are limitations, such as potential biases, lengthy review times, and variability in the quality of reviews. The blind peer-review method can help mitigate potential conflicts of interest or undue influence between reviewers and authors. Additionally, employing advanced technologies such as artificial intelligence to assist in initial manuscript assessments could be useful as an initial step.

According to Dr. Nardin, a reviewer should possess several key qualities. Patience is crucial, as authors spend months producing and submitting their manuscripts, and reviewers must carefully evaluate all aspects of the work to suggest substantial improvements when necessary. Moreover, reviewers should have a strong understanding of the subject matter, attention to detail, and the ability to provide constructive and unbiased feedback.

Dr. Nardin believes that peer reviewing is a vital component of the scientific process, ensuring the accuracy, quality, and integrity of published research. He adds, "Contributing to this process allows me to play a crucial role in advancing knowledge within my field. This process helps me stay updated with the latest research and developments, which can inform and inspire my work, fostering continuous learning and professional growth. Lastly, it also sharpens my critical thinking and analytical skills, as I must rigorously evaluate the methodologies, data, and conclusions presented in manuscripts."



11. Interviews with Outstanding Authors (2024)

In 2024, many TBCR authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspective and insightful view as authors.

Carlos H Barrios



ensuring credibility, validity, and academanuscript by experts, who assess the robust, the conclusions are supported review maintains the trustworthiness of improving several different aspects of of the experiment, analysis of the resumproving the quality of the presented

Dr. Carlos H. Barrios is a medical oncologist working in Porto Alegre, Brazil. Dedicated mainly to Breast Cancer

Simone Nardin



months producing and submitting their when necessary. Moreover, reviewers s constructive and unbiased feedback.

Dr. Nardin believes that peer reviewing He adds, "Contributing to this process & the latest research and developments, sharpens my critical thinking and analy.

Simone Nardin graduated from the University of Eastern Piedmont under the guidance of Professor Alessandra

Beat Thürlimann



en International Breast Cancer Cor

Prof. Beat Thürlimann is board-certified in internal medicine and oncology/hematology. He served for many years as President of the Swiss Group for Clinical Cancer Research SAKK and of the International Breast Cancer Study Group IBCSG as well as Deputy Editor-in-Chief of the European Journal of Cancer. During his professional life, he advised several institutions in the public health sector such as cancer registries, quality assurance committee of mammography screening, Cancer League, Swiss Federal Office of Public Health and many other. He is also a Co-organizer of the St. Gallen Breast Cancer Conferences and St. Gallen Consensus Meeting. His clinical work has focused on breast cancer and gynecological tumors for more than 40 years. He works presently with SwissBreastCare in Zürich, Switzerland, as Senior Expert Consultant. More information about Prof. Thürlimann can be found here.

In Prof. Thürlimann's opinion, there is a large spectrum of essential elements of an academic paper, but not all might be covered in one manuscript. Good academic papers generally include meaningful research results on biology and understanding of the disease and its host rather than to focus on latest results which are likely to be old in 2 or 3 years. Such papers should be well written, concise and easy to understand even for non-subspecialists. Furthermore, they should guarantee open access.

In constructing a paper, Prof. Thürlimann believes it is important for authors to focus on the message, which is concisely written, rather than including all aspects. This will allow rapid communication and avoid undue delay, which is not infrequently seen with publication of academic papers. And last but not least, the lead author needs to push continuously to get the manuscript submitted in reasonable time.

"TBCR is a young entity open for new avenues, with service-oriented staff who gives rapid feedback. And the journal is open access, facilitating scientific communication," says Prof. Thürlimann.



12. Interviews with Editorial Board Members (2024)

TBCR features a distinguished editorial board, the members of which continue to instill the power of their expertise for the journal's development. By launching this column, we are glad to introduce to you some of them in the form of interviews, in which they will share their unique career experiences and perspectives. We believe their insights will shed light on the knowledge of related fields.



Figure 1 Dr. Murali M. Yallapu

Interview

TBCR: What inspired you to pursue

Dr. Yallapu: Throughout my academic and cancer stood out as one of the mo cells is fascinating, yet tumors have ev Interview my deep interest in the field of cancer revolutionize therapeutic delivery. This reducing systemic toxicity. By integrati advance cancer therapy, improve patie



Figure 1 Dr. Christine U. Lee

TBCR: What initially inspired you to p

Dr. Lee: Early in my career, I worked as a abdominal computed tomography (CTs), by body radiologists. At one point, our br breast radiology offered opportunities an procedures. I also found the collaborative



Figure 1 Prof. Délio Marques Conde

Interview


TBCR: What initially inspired you to pursue a career in gynecology and obstetrics?

Prof. Conde: During medical school, we observed our professors a lot, even if not consciously. The example set by our professors is an eternal source of inspiration for us to invest in and pursue a particular specialty. I would also like to add that the particularities of gynecology and obstetrics, and their broad area of expertise, have always encouraged me.

In addition, I always had in mind that I would dedicate myself to treating breast diseases, especially breast cancer. To specialize in breast surgery in Brazil, you must first have completed a residency in general surgery or gynecology and obstetrics. That was what I did, I pursued my goal. I feel very happy with my choice, and it is rewarding.



13. Cover Image Display







Vol 5 (April 2024)



Vol 5 (July 2024)



Vol 5 (October 2024)

In TBCR, different cover images are designed to highlight the featured article in each issue.



14. 2025 Events

➤ 19thSt. Gallen International Breast Cancer Conference 2025

Editor-in-Chief, Prof. Jiang will attend this meeting with his team in Vienna. Looking forward to communicating with experts who focus on breast cancer around the world.

➤ CSCO BC 2025 in Beijing, China

The conference of Chinese Society of Clinical Oncology Breast Cancer will be held in Beijing in 2025, domestic and international breast cancer doctors will attend this meeting. TBCR editorial team also anticipates working closely with the doctors.

Launch the special series focusing on different topics in the field of breast cancer

TBCR editorial office plans to launch the special series to explore the frontier topics on breast cancer.



14. Introduction to the Publisher AME

AME Publishing Company

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world
- 60+ peer-reviewed journals
- 34 indexed in Web of Science (SCIE/ESCI)
- 21 indexed in PubMed/PubMed Central (PMC)/Medline
- 200+ Medical Books
- 80+ Medical Books in English
- 120+ Medical Books in Chinese
- 150+ Electronic Editions